Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Rating of “Moderate Buy” from Brokerages

Compass Therapeutics, Inc. (NASDAQ:CMPX) has received an average recommendation of “Moderate Buy” from the fourteen research firms that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, twelve have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $13.3636.

Several equities research analysts recently issued reports on the company. Raymond James Financial reissued an “outperform” rating and issued a $9.00 price objective on shares of Compass Therapeutics in a research note on Tuesday, January 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Compass Therapeutics in a research report on Wednesday, January 21st. Canaccord Genuity Group set a $13.00 price objective on shares of Compass Therapeutics in a research report on Wednesday, February 4th. Craig Hallum assumed coverage on shares of Compass Therapeutics in a research note on Friday, February 13th. They issued a “buy” rating and a $15.00 price objective on the stock. Finally, Wall Street Zen raised shares of Compass Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, February 16th.

Compass Therapeutics Stock Performance

Shares of CMPX stock opened at $6.17 on Friday. Compass Therapeutics has a 1 year low of $1.33 and a 1 year high of $6.88. The business’s fifty day moving average is $5.78 and its 200-day moving average is $4.60. The stock has a market cap of $1.10 billion, a PE ratio of -13.71 and a beta of 1.46.

Hedge Funds Weigh In On Compass Therapeutics

A number of institutional investors have recently modified their holdings of CMPX. Russell Investments Group Ltd. lifted its position in Compass Therapeutics by 3,933.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company’s stock worth $27,000 after acquiring an additional 7,592 shares during the last quarter. Creative Planning acquired a new stake in shares of Compass Therapeutics in the second quarter valued at about $30,000. Flagship Harbor Advisors LLC bought a new position in shares of Compass Therapeutics in the fourth quarter worth about $32,000. Strs Ohio acquired a new position in shares of Compass Therapeutics during the 1st quarter worth about $34,000. Finally, Apollon Wealth Management LLC acquired a new position in shares of Compass Therapeutics during the 3rd quarter worth about $35,000. Institutional investors own 68.43% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.